A Phase I Trial of A SRC Kinase Inhibitor, Dasatinib,in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Recurrent Ovarian, Peritoneal, and Tubal Cancer.
Phase of Trial: Phase I
Latest Information Update: 27 Dec 2012
At a glance
- Drugs Dasatinib (Primary) ; Carboplatin; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Jun 2010 Planned end date changed from Sep 2010 to Sep 2011 as reported by ClinicalTrials.gov.
- 07 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.